Cargando…

Developing and user testing new pharmacy label formats—A study to inform labelling standards

BACKGROUND: Dispensed prescription medicine labels (prescription labels) are important information sources supporting safe and appropriate medicines use. OBJECTIVE: To develop and user test patient‐centred prescription label formats. METHODS: Five stages: developing 12 labels for four fictitious med...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Vivien, Aslani, Parisa, Raynor, David K., Shipp, Diana, Parkinson, Brian, Lalor, Daniel, Sobey, Andrew, Gilbert, Alice, Crofton, Jackie, Young, Joanne, Carter, Sophie, Poon, Wing, Chitlangia, Shrada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369108/
https://www.ncbi.nlm.nih.gov/pubmed/34076940
http://dx.doi.org/10.1111/hex.13203
_version_ 1783739221169668096
author Tong, Vivien
Aslani, Parisa
Raynor, David K.
Shipp, Diana
Parkinson, Brian
Lalor, Daniel
Sobey, Andrew
Gilbert, Alice
Crofton, Jackie
Young, Joanne
Carter, Sophie
Poon, Wing
Chitlangia, Shrada
author_facet Tong, Vivien
Aslani, Parisa
Raynor, David K.
Shipp, Diana
Parkinson, Brian
Lalor, Daniel
Sobey, Andrew
Gilbert, Alice
Crofton, Jackie
Young, Joanne
Carter, Sophie
Poon, Wing
Chitlangia, Shrada
author_sort Tong, Vivien
collection PubMed
description BACKGROUND: Dispensed prescription medicine labels (prescription labels) are important information sources supporting safe and appropriate medicines use. OBJECTIVE: To develop and user test patient‐centred prescription label formats. METHODS: Five stages: developing 12 labels for four fictitious medicines of varying dosage forms; diagnostic user testing of labels (Round 1) with 40 consumers (each testing three labels); iterative label revision, and development of Round 2 labels (n = 7); user testing of labels (Round 2) with 20 consumers (each testing four labels); labelling recommendations. Evaluated labels stated the active ingredient and brand name, using various design features (eg upper case and bold). Dosing was expressed differently across labels: frequency of doses/day, approximate times of day (eg morning), explicit times (eg 7 to 9 AM), and/or explicit dosing interval. Participants’ ability to find and understand medicines information and plan a dosing schedule were assessed. RESULTS: Participants demonstrated satisfactory ability to find and understand the dosage for all label formats. Excluding active ingredient and dosing schedule, 14/19 labels (8/12 in Round 1; 6/7 in Round 2) met industry standard on performance. Participants’ ability to correctly identify the active ingredient varied, with clear medicine name sign‐posting enabling all participants evaluating these labels to find and understand the active ingredient. When planning a dosing schedule, doses were correctly spaced if the label stated a dosing interval, or frequency of doses/day. Two‐thirds planned appropriate dosing schedules using a dosing table. CONCLUSIONS: Effective prescription label formatting and sign‐posting of active ingredient improved communication of information on labels, potentially supporting safe medicines use. PATIENT AND PUBLIC INVOLVEMENT: Consumers actively contributed to the development of dispensed prescription medicine labels. Feedback from consumers following the first round was incorporated in revisions of the labels for the next round. Patient and public involvement in this study was critical to the development of readable and understandable dispensed prescription medicine labels.
format Online
Article
Text
id pubmed-8369108
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83691082021-08-23 Developing and user testing new pharmacy label formats—A study to inform labelling standards Tong, Vivien Aslani, Parisa Raynor, David K. Shipp, Diana Parkinson, Brian Lalor, Daniel Sobey, Andrew Gilbert, Alice Crofton, Jackie Young, Joanne Carter, Sophie Poon, Wing Chitlangia, Shrada Health Expect Original Articles BACKGROUND: Dispensed prescription medicine labels (prescription labels) are important information sources supporting safe and appropriate medicines use. OBJECTIVE: To develop and user test patient‐centred prescription label formats. METHODS: Five stages: developing 12 labels for four fictitious medicines of varying dosage forms; diagnostic user testing of labels (Round 1) with 40 consumers (each testing three labels); iterative label revision, and development of Round 2 labels (n = 7); user testing of labels (Round 2) with 20 consumers (each testing four labels); labelling recommendations. Evaluated labels stated the active ingredient and brand name, using various design features (eg upper case and bold). Dosing was expressed differently across labels: frequency of doses/day, approximate times of day (eg morning), explicit times (eg 7 to 9 AM), and/or explicit dosing interval. Participants’ ability to find and understand medicines information and plan a dosing schedule were assessed. RESULTS: Participants demonstrated satisfactory ability to find and understand the dosage for all label formats. Excluding active ingredient and dosing schedule, 14/19 labels (8/12 in Round 1; 6/7 in Round 2) met industry standard on performance. Participants’ ability to correctly identify the active ingredient varied, with clear medicine name sign‐posting enabling all participants evaluating these labels to find and understand the active ingredient. When planning a dosing schedule, doses were correctly spaced if the label stated a dosing interval, or frequency of doses/day. Two‐thirds planned appropriate dosing schedules using a dosing table. CONCLUSIONS: Effective prescription label formatting and sign‐posting of active ingredient improved communication of information on labels, potentially supporting safe medicines use. PATIENT AND PUBLIC INVOLVEMENT: Consumers actively contributed to the development of dispensed prescription medicine labels. Feedback from consumers following the first round was incorporated in revisions of the labels for the next round. Patient and public involvement in this study was critical to the development of readable and understandable dispensed prescription medicine labels. John Wiley and Sons Inc. 2021-06-02 2021-08 /pmc/articles/PMC8369108/ /pubmed/34076940 http://dx.doi.org/10.1111/hex.13203 Text en © 2021 The Authors. Health Expectations published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Tong, Vivien
Aslani, Parisa
Raynor, David K.
Shipp, Diana
Parkinson, Brian
Lalor, Daniel
Sobey, Andrew
Gilbert, Alice
Crofton, Jackie
Young, Joanne
Carter, Sophie
Poon, Wing
Chitlangia, Shrada
Developing and user testing new pharmacy label formats—A study to inform labelling standards
title Developing and user testing new pharmacy label formats—A study to inform labelling standards
title_full Developing and user testing new pharmacy label formats—A study to inform labelling standards
title_fullStr Developing and user testing new pharmacy label formats—A study to inform labelling standards
title_full_unstemmed Developing and user testing new pharmacy label formats—A study to inform labelling standards
title_short Developing and user testing new pharmacy label formats—A study to inform labelling standards
title_sort developing and user testing new pharmacy label formats—a study to inform labelling standards
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369108/
https://www.ncbi.nlm.nih.gov/pubmed/34076940
http://dx.doi.org/10.1111/hex.13203
work_keys_str_mv AT tongvivien developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT aslaniparisa developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT raynordavidk developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT shippdiana developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT parkinsonbrian developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT lalordaniel developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT sobeyandrew developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT gilbertalice developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT croftonjackie developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT youngjoanne developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT cartersophie developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT poonwing developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards
AT chitlangiashrada developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards